INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
Public company

TERNTerns Pharmaceuticals, Inc.

CIK 0001831363

EDGAR filingsOpen in network
Disclosed transactions15
Buys / sells0 / 3
Max Insider Score23
Connections4with evidence

TERN · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
0
BL
Burroughs Amy L.Director, Chief Executive Officer
TERNTerns Pharmaceuticals, Inc.
Option exercise · 10b5-1 plan
M—
14.6K sh
Jan 15, 2026Jan 16, 2026
traded Jan 15, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 5, 2026
  • ← Insider ofevidence
    Kuriakose EmilChief Medical Officer · Jan 16, 2026
  • ← Insider ofevidence
    Burroughs Amy L.Director, Chief Executive Officer · Jan 16, 2026
  • ← Insider ofevidence
    Quigley Jill M.Director · Nov 5, 2025
0
BL
Burroughs Amy L.Director, Chief Executive Officer
TERNTerns Pharmaceuticals, Inc.
Grant or award · 10b5-1 plan
A
—
300.0K sh
Jan 14, 2026
Jan 16, 2026
traded Jan 14, 2026
+2d
SEC FORM 4

Evidence

0
BL
Burroughs Amy L.Director, Chief Executive Officer
TERNTerns Pharmaceuticals, Inc.
Option exercise · 10b5-1 plan
M—
27.1K sh
Jan 15, 2026Jan 16, 2026
traded Jan 15, 2026
+1dSEC FORM 4

Evidence

0
BL
Burroughs Amy L.Director, Chief Executive Officer
TERNTerns Pharmaceuticals, Inc.
Option exercise · 10b5-1 plan
M—
27.1K sh
Jan 15, 2026Jan 16, 2026
traded Jan 15, 2026
+1dSEC FORM 4

Evidence

21
KE
Kuriakose EmilChief Medical Officer
TERNTerns Pharmaceuticals, Inc.
Grant or award
A—
56.3K sh
Jan 14, 2026Jan 16, 2026
traded Jan 14, 2026
+2dSEC FORM 4

Evidence

9
KE
Kuriakose EmilChief Medical Officer
TERNTerns Pharmaceuticals, Inc.
Grant or award
A—
112.5K sh
Jan 14, 2026Jan 16, 2026
traded Jan 14, 2026
+2dSEC FORM 4

Evidence

11
BL
Burroughs Amy L.Director, Chief Executive Officer
TERNTerns Pharmaceuticals, Inc.
Grant or award · 10b5-1 plan
A—
150.0K sh
Jan 14, 2026Jan 16, 2026
traded Jan 14, 2026
+2dSEC FORM 4

Evidence

6
BL
Burroughs Amy L.Director, Chief Executive Officer
TERNTerns Pharmaceuticals, Inc.
Option exercise · 10b5-1 plan
M$126K
27.1K sh
Jan 15, 2026Jan 16, 2026
traded Jan 15, 2026
+1dSEC FORM 4

Evidence

6
BL
Burroughs Amy L.Director, Chief Executive Officer
TERNTerns Pharmaceuticals, Inc.
Option exercise · 10b5-1 plan
M$126K
27.1K sh
Jan 15, 2026Jan 16, 2026
traded Jan 15, 2026
+1dSEC FORM 4

Evidence

2
BL
Burroughs Amy L.Director, Chief Executive Officer
TERNTerns Pharmaceuticals, Inc.
Option exercise · 10b5-1 plan
M$68K
14.6K sh
Jan 15, 2026Jan 16, 2026
traded Jan 15, 2026
+1dSEC FORM 4

Evidence

18
BL
Burroughs Amy L.Director, Chief Executive Officer
TERNTerns Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$2.27M
61.2K sh
Jan 15, 2026Jan 16, 2026
traded Jan 15, 2026
+1dSEC FORM 4

Evidence

11
BL
Burroughs Amy L.Director, Chief Executive Officer
TERNTerns Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$282K
7,521 sh
Jan 15, 2026Jan 16, 2026
traded Jan 15, 2026
+1dSEC FORM 4

Evidence

23
QM
Quigley Jill M.Director
TERNTerns Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$441K
24.5K sh
Nov 4, 2025Nov 5, 2025
traded Nov 4, 2025
+1dSEC FORM 4

Evidence

0
QM
Quigley Jill M.Director
TERNTerns Pharmaceuticals, Inc.
Option exercise · 10b5-1 plan
M—
24.5K sh
Nov 4, 2025Nov 5, 2025
traded Nov 4, 2025
+1dSEC FORM 4

Evidence

2
QM
Quigley Jill M.Director
TERNTerns Pharmaceuticals, Inc.
Option exercise · 10b5-1 plan
M$227K
24.5K sh
Nov 4, 2025Nov 5, 2025
traded Nov 4, 2025
+1dSEC FORM 4

Evidence

Source error

Price history for TERN is unavailable.

An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.